Liver Disease Information

In Your Area

Contact Us

American Liver Foundation
39 Broadway, Suite 2700
New York, New York 10006

212-668-1000 Tel
212-483-8179 Fax

Home > About Us > About Advocacy > Hepatitis A and Vaccination

Hepatitis A and Vaccination

Position Statement on Hepatitis A and Vaccination

  • WHEREAS, the hepatitis A virus (HAV) is hardy and continuously reintroduced into the US;
  • WHEREAS, that HAV is an important illness, the scope of which has been underestimated;
  • WHEREAS, that outbreaks of HAV are still a threat that take a toll on all Americans;
  • WHEREAS, the incidence of hepatitis A is more common than hepatitis B or hepatitis C;
  • WHEREAS, incidence of hepatitis A goes beyond well-defined risk groups (e.g., people with chronic liver disease, travelers, men who have sex with men);
  • WHEREAS, hepatitis A is estimated to infect some 35,000 people a year;
  • WHEREAS, hepatitis A hospitalizes some 22% of those adults infected, an estimated 100 of whom die annually;
  • WHEREAS, children are a reservoir for hepatitis A infection and represent the single most important point of intervention in the effort to eliminate the transmission of the disease
  • WHEREAS, routine HAV vaccination of children to climinate community-wide HAV is a tactic that both works and is cost effective;


  • Education efforts should be increased to underscore the urgency of hepatitis A vaccination to at-risk groups (e.g., people with chronic liver disease, travelers, men who have sex with men);

  • Policy makers should make hepatitis A vaccination universal for children nationwide;

  • Education and advocacy should be pursued at the federal and state level to accomplish this;

  • The American Liver Foundation will identify steps to promote this resolution.

Page updated: October 4th, 2011


末末末末末末末末 Begin Code for Siteimprove Analytics 末末末末